Navigation Links
Penn biochemist receives NIH New Innovator's Award
Date:10/5/2007

PHILADELPHIA - James Shorter, PhD, Assistant Professor of Biochemistry and Biophysics at the University of Pennsylvania School of Medicine, has been named an inaugural recipient of the 2007 NIH Director's New Innovator Award. This highly prestigious award totals $1.5 million in direct costs over five years to each of 29 investigators, many of whom are in the early stages of their careers. More than 2,100 applications were received for this extremely competitive program.

As a key component of the National Institutes of Health (NIH) Roadmap for Medical Research, the New Innovator Award program supports exceptionally creative early-career scientists who take highly innovative approaches to major challenges in biomedical research. Shorter will develop biochemical methods to combat diseases caused by nerve degeneration, such as Parkinsons, Alzheimers, and Huntingtons.

Novel ideas and new investigators are essential ingredients for scientific progress, and the creative scientists we recognize with NIH Directors Pioneer Awards and NIH Directors New Innovator Awards are well-positioned to make significantand potentially transformativediscoveries in a variety of areas, said NIH Director Elias A. Zerhouni, MD.

This award is an honor, and a relief, in a way, to now be able to focus on my research in a significant way, says Shorter. Shorters lab seeks to understand how cells prevent, reverse, or even promote the formation of amyloid and prion fibers, extremely stable protein aggregates implicated in many neurodegenerative diseases. He aims to test his ideas using a panel of proteins that are implicated in human disease to search for potential cures for these disorders.

When amyloid fibers grow and divide they can be infectious, and are then termed prions. Prion and amyloid formation are associated with some of the most devastating neurodegenerative diseases confronting humans, including Alzheimer's disease, Parkinson's disease, and vari
'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert

Page: 1 2

Related biology news :

1. Biochemists report discovery of structure of major piece of telomerase; implications for cancer
2. UCR biochemist goes to Washington with high-protein corn
3. Precision biochemistry tracks DNA damage in fish
4. DuPonts first biologically derived polymer receives global recognition
5. OneWorld Health drug receives Orphan designation from U.S. and European regulatory agencies
6. Research on antibiotics receives historical recognition
7. Anthrax test, developed by army and CDC, receives FDA approval
8. Research team receives $7.5 million to study cassava
9. NJIT Presidential Award winner takes stem cell research another step
10. TGen awarded $7.1 million to accelerate brain disease research
11. Virtual microscopy project wins educational technology award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Frontiers in Plant Science , ... gene content and promoter evolution among grasses , ... of stretches of DNA that undergo little change in ... not code for any proteins. Some of these evolutionarily ... to regulate the expression of other genes or the ...
(Date:5/23/2013)... new mechanism by which estrogen suppresses lipid synthesis in ... new approach toward treating certain liver diseases. , ... they are changing long-held views in the field. Study ... journal Science Signaling . , "The dogma in ... that only receptors located in the nucleus respond to ...
(Date:5/23/2013)... medics have succeeded in treating cerebral palsy with autologous ... damage, a 2.5 year old boy had been in ... survival. Just two months after treatment with the cord ... the following months, the child learned to speak simple ... from a Korean study, dispel the long-held doubts about ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2First successful treatment of pediatric cerebral palsy with autologous cord blood 2
... assistant at the University of North Carolina Hospitals arrived ... a glowing track record in helping to repair heart ... perform gastric bypass operations for morbid obesity. , The ... Surgical System, manufactured by Intuitive Surgical. UNC currently is ...
... University of North Carolina Hospitals arrived in February sporting ... record in helping to repair heart valves, remove cancerous ... operations for morbid obesity. , The new arrival is ... by Intuitive Surgical. UNC currently is the only gynecological ...
... aquatic plants respond to plant disease and climate ... say plant pathologists with The American Phytopathological Society ... University, Ithaca, NY, many aquatic plants possess unique ... study, plant pathologists may be able to apply ...
Cached Biology News:FDA: 'Highly Unlikely' Green Tea Lowers Cancer Risk 2FDA: 'Highly Unlikely' Green Tea Lowers Cancer Risk 3Screen all at risk for HIV, plus pregnant women 2Screen all at risk for HIV, plus pregnant women 3
(Date:5/23/2013)... Yonkers, NY (PRWEB) May 23, 2013 ... GRAPHALLOY® self-lubricating bushings mounted in stainless ... and self-lubricating properties of GRAPHALLOY with the application ... GRAPHALLOY Stainless Steel Pillow Blocks work exceptionally ... other corrosive or hostile liquids such as acids, ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 PI’s ... wide and provide 15 mm travel range with ... The small dimensions make these new positioners the ... spaces. A vacuum rated version is also available. ... specifications and datasheets can be found at: , ...
(Date:5/23/2013)... FL (PRWEB) May 23, 2013 On ... made trips to supermarkets to search for the growing ... store aisles. Results from a year long study were ... level in foods, specifically meats, over previous years. For ... how the growth of antibiotic resistant bacteria in food, ...
(Date:5/23/2013)... DIEGO , May 23, 2013  Verenium Corporation ... company focused on the development and commercialization of high-performance ... , Chief Financial Officer, will present at two upcoming ... Mr. Black will present at the Second Annual Marcum ... the Grand Hyatt Hotel in New York City.  The ...
Breaking Biology Technology:Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3
... 1:30 p.m. Eastern Time Today, GAITHERSBURG, Md., March ... financial results and corporate progress for,the full year ended ... we have further demonstrated that Iomai,s,vaccine and immunostimulant patches ... president and chief executive officer,of Iomai. "This lays the ...
... HILLS, Mass., March 6 Joseph F. Finn, ... of ActivBiotics, announced,today that the Office of Orphan ... has granted Orphan Drug Designation for M40403 for ... oral mucositis (OM),in cancer patients., The development ...
... EntreMed, Inc.,(Nasdaq: ENMD ), a clinical-stage pharmaceutical ... inflammatory diseases, today,reported results for the three months ... http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ), For fiscal year ... 2006. For the year ended December 31, 2007, ...
Cached Biology Technology:Iomai Announces Year-End 2007 Financial Results and Business Progress 2Iomai Announces Year-End 2007 Financial Results and Business Progress 3Iomai Announces Year-End 2007 Financial Results and Business Progress 4Iomai Announces Year-End 2007 Financial Results and Business Progress 5Iomai Announces Year-End 2007 Financial Results and Business Progress 6ActivBiotics Receives FDA Orphan Drug Designation for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis of Cancer 2ActivBiotics Receives FDA Orphan Drug Designation for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis of Cancer 3EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results 2EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results 3EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results 4EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results 5
... Sepharose 4B, 10 ... purification of calmodulin-binding ... of calmodulin-regulated proteins ... cells. Category: Chromatography ...
Immunogen: Secretory component isolated from human colostrum. Storage: 4 C...
... The PinPoint™ Vector Sequencing Primer is ... PinPoint™ Xa Vectors (Cat.# V2031, V2051, V2061). ... Xa site at nucleotides 325343, approximately 4050 ... region and can be used to determine ...
Negative Control, eluted and packaged aseptically in 20l of 10mM Tris-HCL, pH 8.0, 1 mM EDTA, 5 years at either 4°C or -20°C...
Biology Products: